Bank Of Nova Scotia Neurocrine Biosciences Inc Transaction History

Bank Of Nova Scotia

$47.5 Billion
Q1 2024

A detailed history of Bank Of Nova Scotia transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Bank Of Nova Scotia holds 7,246 shares of NBIX stock, worth $996,252. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,246

Previous 8,216 11.81%

Holding current value

$996,252

Previous $1.08 Million 7.67%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$130.4 - $143.74 $126,488 - $139,427	-970 Reduced 11.81%	7,246 $999,000
Q4 2023 Feb 12, 2024	BUY	$106.07 - $132.76 $189,334 - $236,976	1,785 Added 27.76%	8,216 $1.08 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $224,237 - $279,283	-2,385 Reduced 27.05%	6,431 $723,000
Q2 2023 Aug 03, 2023	SELL	$89.53 - $104.87 $10.6 Million - $12.5 Million	-118,734 Reduced 93.09%	8,816 $831,000
Q1 2023 May 11, 2023	SELL	$94.11 - $123.02 $1.2 Million - $1.57 Million	-12,768 Reduced 9.1%	127,550 $12.9 Million

Q4 2022 Feb 09, 2023	SELL	$106.72 - $127.06 $12.3 Million - $14.6 Million	-114,985 Reduced 45.04%	140,318 $16.8 Million
Q3 2022 Nov 10, 2022	BUY	$92.03 - $107.81 $22.4 Million - $26.3 Million	243,505 Added 2063.95%	255,303 $27.1 Million
Q2 2022 Aug 08, 2022	BUY	$75.79 - $100.07 $894,170 - $1.18 Million	11,798 New	11,798 $1.15 Million
Q2 2022 Aug 05, 2022	SELL	$75.79 - $100.07 $931,080 - $1.23 Million	-12,285 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$72.45 - $94.81 $398,619 - $521,644	5,502 Added 81.11%	12,285 $1.15 Million
Q4 2021 Feb 11, 2022	BUY	$79.65 - $106.22 $540,265 - $720,490	6,783 New	6,783 $578,000

Others Institutions Holding NBIX

# of Institutions

628

Shares Held

94.4M

Call Options Held

505K

Put Options Held

343K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Nova Scotia, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Nova Scotia with notifications on news.

Account

Bank Of Nova Scotia Neurocrine Biosciences Inc Transaction History